| Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment. | |
| | |
MedLine Citation:
|
PMID: 19638079 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chemotherapy plays an important role in the treatment of gastric cancer both in adjuvant or advanced settings. Recent randomized trials in Japan have proved that S-1, a novel fluoropyrimidine derivative, and cisplatin are the most promising agents. However, both the efficacy and toxicity of a given regimen vary widely among patients due to the inherited variability of genes that involve drug anabolism and catabolism. A narrow therapeutic index of antitumor agents, i.e. a given regimen being too toxic and/or less effective to some segment of patients, prevents the overall improvement of treatment outcomes. Pharmacogenetics, a research field elucidating genetic polymorphism in drug metabolizing enzymes, may contribute to identifying patients who benefit from chemotherapy or who will experience life-threatening toxicity. There are several crucial enzymes identified involving anabolism and the catabolism of fluoropyrimidine and cisplatin, including dihydropyrimidine dehydrogenase, thymidylate synthase, orotate phosphoribosyl transferase, glutathione S transferase, and excision repair cross complementary group. Various polymorphisms and ethnic variabilities of these genes have been elucidated. This review highlights variations within biological functions, detection systems, and possible clinical applications of these enzymatic polymorphisms. This knowledge provides a tool to determine an optimum regimen according to the patient's drug metabolizing characteristics. This stance will contribute to establishing individualized therapies for gastric cancer, which offers superior efficacy with a minimal chance of severe toxicity. |
| | |
Authors:
|
Shouji Shimoyama |
Related Documents
:
|
10099659 - Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrim... 8484979 - Oral tegafur in the treatment of metastatic breast cancer: a phase ii study. 14754469 - Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer ove... 11313169 - Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. 8638189 - Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. 12952569 - Capecitabine-related neurotoxicity presenting as trismus. 20607829 - Epigenetic regulation of cancer growth by histone demethylases. 21831619 - Cytotoxic activity of secondary metabolites derived from artemisia annua l. towards can... 11923519 - Matrix metalloproteinase inhibitors and cancer: trials and tribulations. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of gastroenterology and hepatology Volume: 24 ISSN: 1440-1746 ISO Abbreviation: J. Gastroenterol. Hepatol. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-07-29 Completed Date: 2010-12-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8607909 Medline TA: J Gastroenterol Hepatol Country: Australia |
Other Details:
|
Languages: eng Pagination: 970-81 Citation Subset: IM |
Affiliation:
|
Gastrointestinal Unit, Settlement Clinic, Towa, Adachi-ku, Tokyo, Japan. shimoyama@apost.plala.or.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antimetabolites, Antineoplastic
/
pharmacology* Cisplatin / pharmacology* DNA Repair Dihydrouracil Dehydrogenase (NADP) / genetics Drug Resistance, Neoplasm / genetics Glutathione Transferase / genetics Humans Methylenetetrahydrofolate Reductase (NADPH2) / genetics Orotate Phosphoribosyltransferase / genetics Pharmacogenetics* Pyrimidines / pharmacology* Stomach Neoplasms / drug therapy*, enzymology, genetics* Thymidylate Synthase / genetics |
| Chemical | |
Reg. No./Substance:
|
0/Antimetabolites, Antineoplastic; 0/Pyrimidines; 15663-27-1/Cisplatin; EC 1.3.1.2/Dihydrouracil Dehydrogenase (NADP); EC 1.5.1.20/Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.45/Thymidylate Synthase; EC 2.4.2.10/Orotate Phosphoribosyltransferase; EC 2.5.1.18/Glutathione Transferase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Toll-like receptors and their role in gastrointestinal disease.
Next Document: A randomized, controlled trial of banding ligation plus drug therapy versus drug therapy alone in th...